Can immunization with Bacillus Calmette-Guérin be improved for prevention or therapy and elimination of chronic Mycobacterium tuberculosis infection?
Introduction: Tuberculosis (TB) is one of the most prevalent infectious diseases in the world. Current vaccination with Mycobacterium bovis BCG can prevent meningeal and disseminated TB in children. However, the success of BCG in preventing latent pulmonary TB infection (LTBI) or its reactivation is rather limited. Evidence suggests that there may be means to improve the efficacy of BCG towards LTBI, therefore raising the possibility of developing new vaccine candidates against LTBI.Areas covered: BCG improvements include the use of purified mycobacterial immunogenic proteins, either from an active or dormant state, like DosR and Rpf antigens, as well as expressing said immunogenic proteins from recombinant BCG strains that harbor and express those specific genes. It also includes boost protein mixtures with synthetic adjuvants or encapsulated within liposomes, as a way to increase and assess a protective immune response during artificial chronic TB produced in animal laboratory models. The references cited were chosen by the authors based on PubMed searches.Expert commentary: Strategies aiming to improve or boost BCG have been receiving increased attention in recent years. With the advent of -omics, it has been possible to dissect several specific stages during mycobacterial infection. Recent experimental models of disease, diagnostic and immunological data obtained from individual M. tuberculosis antigens could introduce promising developments for more effective TB vaccines that may contribute to eliminating the hidden (latent) form of this infectious disease.